Zhong-nan Xu

240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C

Da-Zhi Zhang, Q. Ning, Jun Li, 2022, Journal of viral hepatitis.

A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B

Hong Tang, Wenhong Zhang, Xinyue Chen, 2019, Medicine.

One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Da-Zhi Zhang, Jun Li, Q. Xie, 2022, World journal of clinical cases.

Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks

Hong Tang, Wenhong Zhang, J. Shang, 2021, World journal of clinical cases.